Osteoprotegerin is not associated with angiographic coronary calcification

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 3, 2006, Pages 177-183

  Gogo Jr , Prospero B ^a,b   Schneider, David J ^a   Terrien, Edward F ^a   Sobel, Burton E ^a   Dauerman, Harold L ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Calcium; Inflammation; Osteoprotegerin; Stent

Indexed keywords

C REACTIVE PROTEIN; CD40 LIGAND; CREATININE; HEMOGLOBIN; INTERLEUKIN 6; OSTEOPROTEGERIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY STENT; CREATININE CLEARANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SMOKING;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CALCINOSIS; CARDIOMYOPATHIES; CORONARY ANGIOGRAPHY; CORONARY VESSELS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PROSPECTIVE STUDIES; STENTS;

EID: 33845254567     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-9026-3     Document Type: Article

References (35)

1. Gaspardone A, Crea F, Versaci F et al (1998) Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol 82(4):515-518
2. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA (2000) Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 85(1):92-95, A8
3. Aggarwal A, Schneider DJ, Sobel BE, Dauerman HL (2003) Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. Am J Cardiol 92(8):924-929
4. Chew DP, Bhatt DL, Robbins MA et al (2001) Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 104(9):992-997
5. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88(3):1024-1028
6. Kiechl S, Schett G, Wenning G et al (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175-2180
7. Jono S, Ikari Y, Shioi A et al (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106(10):1192-1194
8. Bucay N, Sarosi I, Dunstan CR et al (1998) osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12(9):1260-1268
9. Min H, Morony S, Sarosi I et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192(4):463-474
10. Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24(7):1161-1170
11. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC (2004) Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 74(1):103-106
12. Collin-Osdoby P (2004) Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 95(11):1046-1057
13. Farb A, Sangiorgi G, Carter AJ et al (1999) Pathology of acute and chronic coronary stenting in humans. Circulation 99(1):44-52
14. Gogo PB Jr, Schneider DJ, Watkins MW, Terrien EF, Sobel BE, Dauerman HL (2005) Systemic inflammation after drug-eluting stent placement. J Thromb Thrombolysis 19(2):87-92
15. Bartel AG, Chen JT, Peter RH, Behar VS, Kong Y, Lester RG (1974) The significance of coronary calcification detected by fluoroscopy. A report of 360 patients. Circulation 49(6):1247-1253
16. Kiechl S, Schett G, Wenning G et al (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175-80
17. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC (2004) Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 74(1):103-106
18. Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24(7):1161-1170
19. Aukrust P, Muller F, Ueland T et al (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100(6):614-620
20. Heeschen C, Dimmeler S, Hamm CW et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348(12):1104-1111
21. Aggarwal A, Schneider DJ, Terrien EF, Sobel BE, Dauerman HL (2004) Increased coronary arterial release of interleukin-1 receptor antagonist and soluble CD40 ligand indicative of inflammation associated with culprit coronary plaques. Am J Cardiol 93(1):6-9
22. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R (2002) Morphological predictors of restenosis after coronary stenting in humans. Circulation 105(25):2974-2980
23. Min H, Morony S, Sarosi I et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192(4):463-474
24. Bucay N, Sarosi I, Dunstan CR et al (1998) osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12(9):1260-1268
25. Castagna MT, Mintz GS, Ohlmann P et al (2005) Incidence, location, magnitude, and clinical correlates of saphenous vein graft calcification: An intravascular ultrasound and angiographic study. Circulation 111(9):1148-1152
26. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC (2003) Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88(3):1024-1028
27. Kiechl S, Schett G, Wenning G et al (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175-80
28. Aggarwal A, Schneider DJ, Terrien EF, Terrien CM Jr, Sobel BE, Dauerman HL (2003) Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 91(11):1346-1349
29. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S et al (2000) Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 21(14):1152-8
30. Kiechl S, Schett G, Wenning G et al (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109(18):2175-2180
31. Min H, Morony S, Sarosi I et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192(4):463-474
32. Farb A, Sangiorgi G, Carter AJ et al (1999) Pathology of acute and chronic coronary stenting in humans. Circulation 99(1):44-52
33. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC (2004) Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 74(1):103-106
34. Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24(7):1161-1170
35. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R (2006) The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47(9):1850-1857